Ludwig Maximilian University Of Munich (Lmu) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| | |
|---|---|
| **Name** | Ludwig Maximilian University of Munich |
| **German Name** | Ludwig-Maximilians-Universität München |
| **Location** | Munich, Bavaria, Germany |
| **Type** | Public Research University |
| **Founded** | 1472 |
| **Website** | [www.lmu.de](https://www.lmu.de) |
| **Nobel Laureates** | 18 |
Ludwig Maximilian University of Munich (LMU) is one of Germany's oldest and most prestigious universities, with a rich history dating back to 1472. Located in Munich, Bavaria, LMU is renowned for its excellence in research and education across a wide range of disciplines, including medicine, neuroscience, and biological sciences.
¶ Neuroscience and Neurodegeneration
LMU Munich houses several major research facilities focused on neurodegenerative diseases:
- Munich Cluster for Systems Neurology (SyNergy): An Excel excellency cluster investigating the molecular mechanisms of neurological disorders including Alzheimer's, Parkinson's, and ALS
- German Center for Neurodegenerative Diseases (DZNE): LMU is a partner site of the DZNE, conducting translational research on Alzheimer's, Parkinson's, and other neurodegenerative conditions
- Institute for Stroke and Dementia Research: Focuses on vascular contributions to cognitive impairment and dementia
- Max Planck Institute of Biochemistry: Collaborating department with LMU on protein misfolding and aggregation diseases
| Disease Area |
Research Focus |
Key Labs/Groups |
| Alzheimer's Disease |
Amyloid and tau pathology, neuroimaging |
Prof. Michael Ewers, Prof. Andreas B. K. Müller |
| Parkinson's Disease |
Alpha-synuclein, LRRK2, prodromal markers |
Prof. Wassilios Meissner |
| ALS |
TDP-43 pathology, C9orf72, therapeutic targets |
Prof. M. St. G. Kaindl |
| Multiple Sclerosis |
Neuroinflammation, demyelination |
Prof. R. Hohlfeld |
- Prof. Dr. Christian Haass: Leading researcher in Alzheimer's disease, known for work on amyloid processing and tau pathology
- Prof. Dr. Thomas G. Oertner: Known for pioneering work in synaptic transmission and neural circuit analysis
- Prof. Dr. Martin K. H. Völkner: Expert in translational neuroscience and drug development for neurodegenerative diseases
LMU offers comprehensive training in neuroscience and neurodegeneration:
- Graduate School of Systemic Neurosciences (GSN): Elite doctoral program in neuroscience
- International Max Planck Research School: Collaborative PhD program with Max Planck Institutes
- Medical Doctor-PhD (MD/PhD) Program: Training physician-scientists in neurodegeneration research
¶ Major Discoveries and Contributions
- Alzheimer's Biomarkers: LMU researchers have contributed significantly to CSF and blood biomarker development for Alzheimer's disease
- Neuroimaging Advances: Development of advanced PET and MRI techniques for early detection of neurodegeneration
- Therapeutic Target Discovery: Identification of novel therapeutic targets in amyloid and tau pathways
LMU maintains active collaborations with:
- German Center for Neurodegenerative Diseases (DZNE)
- Max Planck Society
- European Alzheimer's Disease Consortium
- US institutions (Harvard, MIT, UCSF)
- Japanese research institutions
The study of Ludwig Maximilian University Of Munich (Lmu) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Haass C, et al. (2012). Amyloid beta and Alzheimer's disease: the role of gamma-secretase in amyloid-beta formation. Nat Rev Neurosci. PMID:22770080
- Selkoe DJ, Hardy J. (2016). The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. PMID:27025654
- Hampel H, et al. (2021). The amyloid-beta biomarker in Alzheimer's disease. Nat Rev Neurol. PMID:34050389